These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32667929)

  • 1. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
    Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
    PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
    Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
    Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
    Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
    Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX6 represses tumor growth of clear cell renal cell carcinoma by HMG domain-dependent regulation of Wnt/β-catenin signaling.
    Chen L; Xie Y; Ma X; Zhang Y; Li X; Zhang F; Gao Y; Fan Y; Gu L; Wang L; Zhang X; Fu B
    Mol Carcinog; 2020 Oct; 59(10):1159-1173. PubMed ID: 32794610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma.
    Yoshino H; Yonemori M; Miyamoto K; Tatarano S; Kofuji S; Nohata N; Nakagawa M; Enokida H
    Oncotarget; 2017 Mar; 8(13):20881-20894. PubMed ID: 28152509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in renal cell carcinoma.
    Ni X; Ye C; Yu X; Zhang Y; Hou Y; Zheng Q; Chen Z; Wang L; Weng X; Yang C; Liu X
    Eur J Pharmacol; 2023 Dec; 960():176110. PubMed ID: 37838104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
    Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
    Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NLRC5 mediates cell proliferation, migration, and invasion by regulating the Wnt/β-catenin signalling pathway in clear cell renal cell carcinoma.
    Wang Q; Ding H; He Y; Li X; Cheng Y; Xu Q; Yang Y; Liao G; Meng X; Huang C; Li J
    Cancer Lett; 2019 Mar; 444():9-19. PubMed ID: 30543814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
    Sinha S; Dwivedi N; Tao S; Jamadar A; Kakade VR; Neil MO; Weiss RH; Enders J; Calvet JP; Thomas SM; Rao R
    Oncogene; 2020 Feb; 39(6):1231-1245. PubMed ID: 31616061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway.
    Wang H; Zhang L; Liu H; Yang Y; Lu W; Cao X; Yang X; Qin Q; Song R; Feng D; Wang S; Bai T; He J
    Br J Cancer; 2024 Jul; 131(2):347-360. PubMed ID: 38822145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD276 enhances sunitinib resistance in clear cell renal cell carcinoma by promoting DNA damage repair and activation of FAK-MAPK signaling pathway.
    Zhang ZY; Xu JH; Zhang JL; Lin YX; Ou-Yang J
    BMC Cancer; 2024 May; 24(1):650. PubMed ID: 38802739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rac Signaling Drives Clear Cell Renal Carcinoma Tumor Growth by Priming the Tumor Microenvironment for an Angiogenic Switch.
    Goka ET; Chaturvedi P; Lopez DTM; Lippman ME
    Mol Cancer Ther; 2020 Jul; 19(7):1462-1473. PubMed ID: 32371578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance.
    Feng C; Li Y; Li K; Lyu Y; Zhu W; Jiang H; Wen H
    J Exp Clin Cancer Res; 2021 Sep; 40(1):308. PubMed ID: 34593007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.
    Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT
    Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib in combination with sunitinib renders MCL-1 for degradation and activates autophagy that overcomes sunitinib resistance in renal cell carcinoma.
    Liu T; Yue X; Chen X; Yan R; Wu C; Li Y; Bu X; Han H; Liu RY
    Cell Oncol (Dordr); 2024 Aug; 47(4):1277-1294. PubMed ID: 38393513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTPN3 Inhibits the Growth and Metastasis of Clear Cell Renal Cell Carcinoma via Inhibition of PI3K/AKT Signaling.
    Peng XS; Yang JP; Qiang YY; Sun R; Cao Y; Zheng LS; Peng LX; Lang YH; Mei Y; Li CZ; Meng DF; Liu ZJ; Wang MD; Zhou FJ; Huang BJ; Qian CN
    Mol Cancer Res; 2020 Jun; 18(6):903-912. PubMed ID: 32169891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.